Compare · CTIC vs OCGN
CTIC vs OCGN
Side-by-side comparison of CTI BioPharma Corp. (DE) (CTIC) and Ocugen Inc. (OCGN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. CTIC focuses on Biotechnology: Pharmaceutical Preparations, while OCGN focuses on Biotechnology: Biological Products (No Diagnostic Substances).
- OCGN is the larger of the two at $460.4M, about 2.4x CTIC ($191.5M).
- OCGN has hit the wire 3 times in the past 4 weeks while CTIC has been quiet.
- OCGN has more recent analyst coverage (9 ratings vs 7 for CTIC).
- Company
- CTI BioPharma Corp. (DE)
- Ocugen Inc.
- Price
- -
- -
- Market cap
- $191.5M
- $460.4M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1997
- 2014
- News (4w)
- 0
- 3
- Recent ratings
- 7
- 9
CTI BioPharma Corp. (DE)
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It develops pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Vernalis (R&D) Limited. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.
Ocugen Inc.
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
Latest CTIC
- SEC Form 15-12G filed by CTI BioPharma Corp. (DE)
- SEC Form EFFECT filed by CTI BioPharma Corp. (DE)
- SEC Form EFFECT filed by CTI BioPharma Corp. (DE)
- SEC Form EFFECT filed by CTI BioPharma Corp. (DE)
- SEC Form EFFECT filed by CTI BioPharma Corp. (DE)
- SEC Form EFFECT filed by CTI BioPharma Corp. (DE)
- SEC Form EFFECT filed by CTI BioPharma Corp. (DE)
- SEC Form EFFECT filed by CTI BioPharma Corp. (DE)
- SEC Form EFFECT filed by CTI BioPharma Corp. (DE)
- SEC Form EFFECT filed by CTI BioPharma Corp. (DE)
Latest OCGN
- Ocugen Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa
- Ocugen to Participate in Upcoming July Industry Conferences
- Chief Financial Officer Johnson-Greene Treerita Essalima bought $25,830 worth of shares (21,000 units at $1.23), increasing direct ownership by 4% to 521,000 units (SEC Form 4)
- SEC Form 4 filed by Director Kompella Uday
- SEC Form 4 filed by Director Chandrasekhar Satishchandran
- SEC Form 4 filed by Director Castillo Kirsten
- SEC Form 4 filed by Director Zhang Junge
- SEC Form 4 filed by Director Coleman Blaise
- Ocugen Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events